- Clinical trials of the vaccine against the new coronavirus infection COVID-19 will be carried out on the basis of 48 Central Research Institute of the Ministry of Defense of the Russian Federation, where the safety, immunogenicity and protective efficacy of the genetically engineered vaccines of Ebola hemorrhagic fever, the Middle East respiratory syndrome and universal influenza vaccine have already been studied and successfully tested, - leads the "Kommersant" message agency.
According to TASS, volunteers were selected from various units throughout the country. A total of 45 men and five women were selected. Candidates have undergone preliminary examinations and testing. During the month of e, they revealed no diseases.
Recall that in Rospotrebnador noted that the restrictions on coronavirus will be completely removed only after the vaccine appears against a new infection. In the meantime, don’t be in a hurry with vaccination, I am sure the head of the department of microbiology, virology and immunology of the First MGMU them. Sechenova, Academician of the Russian Academy of Sciences Vitaliy Zverev. First, it is necessary to confirm the safety of the vaccine, since the threat of its use can be fatal, the expert believes.
- Creating a vaccine takes some time. And a significant part of this time is spent studying security. The vaccine needs to be thoroughly studied, to confirm its safety, - said Zverev, stating that in such a short time it is unrealistic to verify the reliability of the drug.
To date, 5 762 664 cases of coronavirus infection have been registered in the world. 367 368 people died. In Russia, 414 878 cases of COVID-19 were detected. 4 855 patients died from the disease.
Earlier it was reported that at the Novosibirsk Center for Virology and Biotechnology Vector, Rospotreunadzor developed a vaccine against COVID-19 that can be instilled into the nose. Her preclinical study is underway.